ES2072875T3 - Conjugados de vip y de sus fragmentos activos con porciones hidrofobicas y preparacion para la utilizacion en el tratamiento de la impotencia masculina. - Google Patents

Conjugados de vip y de sus fragmentos activos con porciones hidrofobicas y preparacion para la utilizacion en el tratamiento de la impotencia masculina.

Info

Publication number
ES2072875T3
ES2072875T3 ES89112463T ES89112463T ES2072875T3 ES 2072875 T3 ES2072875 T3 ES 2072875T3 ES 89112463 T ES89112463 T ES 89112463T ES 89112463 T ES89112463 T ES 89112463T ES 2072875 T3 ES2072875 T3 ES 2072875T3
Authority
ES
Spain
Prior art keywords
treatment
vip
male impotence
conjugates
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89112463T
Other languages
English (en)
Inventor
Illana Gozes
Matityahu Fridkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of ES2072875T3 publication Critical patent/ES2072875T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PRESENTAN COMPOSICIONES FARMACEUTICAS PARA LA APLICACION TRANSDERMICA TOPICA PARA EL TRATAMIENTO DE LA IMPOTENCIA MASCULINA Y COMPOSICIONES PARA EL TRATAMIENTO DEL ASMA Y LA HIPERTENSION. LOS INGREDIENTES ACTIVOS DE TALES COMPOSICIONES SON SELECCIONADOS ENTRE EL PEPTIDO INSTESTINAL VASOACTIVO (VIP) DERIVADAS EFECTIVOS DEL MISMO Y FRAGMENTO EFECTIVOS DEL MISMO. EN LAS COMPOSICIONES PARA EL TRATAMIENTO DE LA IMPOTENCIA MASCULINA ES USADO UN CONJUGADO TRANSDERMICAMENTE EFECTIVO DEL VIP. SUS DERIVADOS O FRAGMENTOS ACOPLADOS A UNA PARTE HIDROFOBICA.
ES89112463T 1988-07-08 1989-07-07 Conjugados de vip y de sus fragmentos activos con porciones hidrofobicas y preparacion para la utilizacion en el tratamiento de la impotencia masculina. Expired - Lifetime ES2072875T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL8705588A IL87055A (en) 1988-07-08 1988-07-08 Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them

Publications (1)

Publication Number Publication Date
ES2072875T3 true ES2072875T3 (es) 1995-08-01

Family

ID=11059032

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89112463T Expired - Lifetime ES2072875T3 (es) 1988-07-08 1989-07-07 Conjugados de vip y de sus fragmentos activos con porciones hidrofobicas y preparacion para la utilizacion en el tratamiento de la impotencia masculina.

Country Status (7)

Country Link
US (1) US5147855A (es)
EP (1) EP0354992B1 (es)
JP (1) JP2682702B2 (es)
AT (1) ATE120091T1 (es)
DE (1) DE68921814T2 (es)
ES (1) ES2072875T3 (es)
IL (1) IL87055A (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447912A (en) * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
ES2124225T3 (es) * 1990-04-25 1999-02-01 Vivus Inc Tratamiento de la disfuncion erectil.
EP0463450B1 (en) * 1990-06-26 1994-02-16 Sanwa Kagaku Kenkyusho Co., Ltd. Vasoactive intestinal polypeptide analogues and use thereof
IL99924A (en) * 1991-10-31 1995-12-31 Yeda Res & Dev Derivatives of structurally modified vip and pharmaceutical compositions containing them
US5998368A (en) * 1991-10-31 1999-12-07 Yeda Research And Development Co. Ltd. Derivatives of structurally modified VIP and pharmaceutical compositions containing them
CA2124672A1 (en) * 1991-12-10 1993-06-24 Tse W. Chang Cytokines with an upaired cysteine residue and conjugates thereof
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
US5382392A (en) * 1993-02-05 1995-01-17 Alliedsignal Inc. Process for fabrication of carbon fiber-reinforced carbon composite material
US5972883A (en) * 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
EP0696919B1 (en) * 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnosis and treatment of erectile dysfunction
US5333621A (en) * 1993-05-28 1994-08-02 Eric Denzer Condom with transdermal vasodilator
US6007836A (en) * 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
IL118003A0 (en) * 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
WO1999002147A1 (en) 1997-07-09 1999-01-21 Androsolutions, Inc. Improved methods and compositions for treating male erectile dysfunction
CA2405728A1 (en) * 2000-07-31 2002-02-07 Dabur Research Foundation Lipid-peptide conjugates for treatment of cancer
US6828304B1 (en) 2000-07-31 2004-12-07 Dabur Research Foundation Peptides for treatment of cancer
AU2002220720B2 (en) 2000-11-28 2006-09-14 Mondobiotech Ag Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
JP2009525946A (ja) 2005-12-20 2009-07-16 デューク・ユニヴァーシティ 増強された薬理学的性質を有する活性物質を送達するための方法および組成物
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
JP5801807B2 (ja) * 2009-08-14 2015-10-28 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 修飾された血管作動性腸管ペプチド
ES2669190T3 (es) 2011-06-06 2018-05-24 Phasebio Pharmaceuticals, Inc. Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión
WO2015172046A1 (en) 2014-05-08 2015-11-12 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
WO2016130518A2 (en) 2015-02-09 2016-08-18 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating muscle disease and disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3879371A (en) * 1971-09-17 1975-04-22 Sami I Said Isolation of vasoactive intestinal peptide
FR2308266A1 (fr) * 1975-04-18 1976-11-12 Telecommunications Sa Procede de transmission dans des reseaux de connexion temporels a grande capacite
EP0018609B1 (de) * 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
US4605641A (en) * 1984-10-09 1986-08-12 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
GB8427651D0 (en) * 1984-11-01 1984-12-05 Beecham Group Plc Compounds
GB8525852D0 (en) * 1985-10-19 1985-11-20 Beecham Group Plc Compounds
JPS62135407A (ja) * 1985-12-10 1987-06-18 Meiji Seika Kaisha Ltd 育毛剤
JPS62246595A (ja) * 1986-04-17 1987-10-27 Eisai Co Ltd 気菅支拡張作用・降圧作用ペプタイド
US4853371A (en) * 1986-06-17 1989-08-01 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4939224A (en) * 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
SE8702520D0 (sv) * 1987-06-16 1987-06-16 Kabigen Ab Mammal intestine hormone precursor
US4935491A (en) * 1987-08-24 1990-06-19 Board Of Regents, The University Of Texas System Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US4935492A (en) * 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides

Also Published As

Publication number Publication date
EP0354992A3 (en) 1991-01-16
DE68921814D1 (de) 1995-04-27
US5147855A (en) 1992-09-15
DE68921814T2 (de) 1995-09-28
ATE120091T1 (de) 1995-04-15
IL87055A0 (en) 1988-12-30
JP2682702B2 (ja) 1997-11-26
JPH0276821A (ja) 1990-03-16
IL87055A (en) 1994-06-24
EP0354992B1 (en) 1995-03-22
EP0354992A2 (en) 1990-02-21

Similar Documents

Publication Publication Date Title
IL87055A0 (en) Topical pharmaceutical compositions
PT951473E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
PT951474E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
FR2757522B1 (fr) Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
ES554967A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido.
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
ES2020738A6 (es) Composiciones farmaceuticas comprendiendo ciclosporinas.
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
ES2038643T3 (es) Procedimiento para la obtencion de una composicion farmaceutica topica.
ATE202931T1 (de) Taxanderivate enthaltende arzneizubereitungen
IT1255723B (it) Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
PT95697A (pt) Processo para a preparacao de composicoes farmaceuticas contendo substancias antiandrogenicamente activas
ES2012339B3 (es) Preparacion oral de ajo y procedimiento para su fabricacion
IL82813A (en) Peptides influencing diuresis,natriuresis and kaliuresis and pharmaceutical compositions containing them
CO4230037A1 (es) Composicion para aplicacion topica a la piel y/o cabello a base de tensioactivo de fosfato y co-tensioactivo
ES2038606T3 (es) Una composicion para la preparacion extemporanea de formulaciones destinadas a aplicaciones topicas para uso farmaceutico y cosmetico.
DK0773782T3 (da) Terpenderivater (sarcodictyiner) anvendelse som antitumormidler
IT1255076B (it) Microsfere biodegradabili ad uso farmaceutico e cosmetico
AR017215A1 (es) Composiciones que contienen generadores de oxido nitrico y uso de dichos generadores para la preparacion de un medicamento util para el tratamiento detrastornos de ojo seco
GB9727424D0 (en) Liposomes containing multiple branch peptide constructions for use against human immunodeficiency virus
MY104088A (en) Peptide-drugs compositions containing (alpha)-aminoboroic acid derivatives.
ES2103422T3 (es) Uso de bilobalida y sus derivados para tratar una infeccion en un individuo y composiciones farmaceuticas destinadas a dicho uso.
ES2010963A4 (es) Derivados de n - cicloalkilaminoetilbenzamida, su sintesis y preparacion farmaceutica
ES2057542T3 (es) Agentes terapeuticos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 354992

Country of ref document: ES